osimertinib
astrazeneca
['sclc', 'lcsm,(-blcsm)', 'nsclc']
#asco23 #lcsm abs8508 it s time to rethink the mngmt of egfr+ nsclc ph2 of neoadj osi in egfr mutant nsclc by 27 pts with stage i-iiia
pr-rate 48%. no pcr.
mpr-rate 15% (4/27) the study did not meet the primary endpoint 
MD PhD, lung oncologist & researcher @IEOufficiale; @myESMO Communication Committee Chair; #LungCancer Molecular target-believer #LCSM